🇺🇸 FDA
Patent

US 12084514

Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof

granted A61KA61K2039/505A61K2039/585

Quick answer

US patent 12084514 (Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof) held by The Board of Regents of the University of Oklahoma expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Oklahoma
Grant date
Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61K2039/585, A61K2239/31, A61K2239/38